GlassScriptPhysician profile
Marshall D Early
NPI 1942528138
$8,678.29
in general payments reported to CMS, 2019-2025
40 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $340 · 2021: $794 · 2022: $1,067 · 2023: $663 · 2024: $2,093 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,889 · Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,888.89 |
| Food and Beverage | $2,328.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,037.98 | 2023-2025 | Venacure 1470 Pro, Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Silk Road Medical, INC. | $1,095.33 | 2019-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| W. L. Gore & Associates, INC. | $740.95 | 2019-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Thoracic Branch Endoprosthesis, Gore Excluder Iliac Branch Endoprosthesis |
| Ge Healthcare | $716.98 | 2022-2025 | |
| Medtronic, INC. | $384.31 | 2021-2025 | Endurant Iis, Abre, Ellipsys Vascular Access System |
| Penumbra, INC. | $328.17 | 2021-2024 | Penumbra System |
| Ethicon US, LLC | $289.00 | 2020-2022 | |
| Tactile Systems Technology INC | $225.13 | 2020-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Intuitive Surgical, INC. | $219.65 | 2019-2022 | |
| Inari Medical, INC. | $199.07 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $153.74 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2020 | |
| Argentum Medical | $101.53 | 2021 | |
| Stryker Corporation | $93.10 | 2025 | Artix Mt |
| Endologix LLC | $89.53 | 2023 | Alto Abdominal Stent Graft System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $86.30 | 2024-2025 | Varithena Administration Pack, Enroute Transcarotid Neuroprotection System |
| Davol INC. | $82.84 | 2024-2025 | Phasix Mesh |
| Artivion, INC. | $55.46 | 2023 | Photofix Decellularized Bovine Pericardium, Bioglue Surgical Adhesive, Vascular |
| Medtronic Vascular, INC. | $54.43 | 2019-2020 | |
| Acell, INC. | $51.43 | 2019-2020 | |
| Lemaitre Vascular, INC. | $44.78 | 2023 | Anastoclip Gc 8cm (Medium), Artegraft Vascular Graft |
| Integra Lifesciences Corporation | $44.57 | 2020-2021 | |
| Reflow Medical INC | $44.24 | 2025 | |
| Innovation Technologies INC | $40.68 | 2022 | |
| Smith+Nephew, INC. | $39.63 | 2019-2025 | Pico, Pico 7 |
| Tela Bio, INC. | $36.35 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $29.89 | 2025 | |
| Conmed Corporation | $29.50 | 2021 | |
| Tei Biosciences INC | $27.64 | 2019 | |
| Potrero Medical, INC. | $25.69 | 2021 | |
| Cordis US Corp. | $24.30 | 2023 | Zephyr |
| Portola Pharmaceuticals, LLC | $22.36 | 2019 | |
| Kerecis Limited | $19.40 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bolton Medical INC | $18.94 | 2024 | Treo Abdominal Stent-Graft System |
| Pfizer INC. | $18.88 | 2023 | |
| Innocoll Pharmaceuticals Limited | $17.64 | 2022 | |
| Baxter Healthcare | $15.04 | 2023 | Peri-Strips Dry |
| Heron Therapeutics, INC. | $14.61 | 2022 | |
| Allergan, INC. | $12.69 | 2021 | |
| Elucent Medical | $11.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Early listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.